Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female and male patients aged 12 to 21 years, inclusive, at the time of Visit 1~* Weight of ≥40 kg~* Documented history of current treatment with Inhaled corticosteroids (ICS) and long-acting β2 agonists (LABA)~* Morning pre-bronchodilator forced expiratory volume in 1 second (FEV1) of \>50% predicted at Visit 1 or Visit 2.~* Airway reversibility (FEV1 \>12% and 200 ml) demonstrated at Visit 1 or Visit 2 using the Maximum Post-bronchodilator Procedure OR~* Airway reversibility documented in the previous 12 months prior to Visit 1~* An exacerbation, 1 or more, that required oral corticosteroids in the previous year OR~* Any condition assessed by patient recall over the previous 2-4 weeks~Exclusion Criteria:~* Clinically important pulmonary disease other than asthma~* Known history of allergy or reaction to the Investigational Product formulation or influenza vaccine~* Receipt of an influenza vaccine within 90 days prior to randomization~* Poorly controlled asthma during the screening period that requires treatment with oral corticosteroids or a hospitalization/emergency room visit for the treatment of asthma~* Acute illness or evidence of significant active infection or known influenza infection during the current flu season

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Benralizumab (Type: EXPERIMENTAL): 1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
- Placebo (Type: PLACEBO_COMPARATOR): 1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).